Press Releases

PDL BioPharma Completes Retirement of $61.7 Million of 2.75% Convertible Notes Due August 2023 for Common Stock INCLINE VILLAGE, Nev., Aug 12, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) announced today that it has completed the retirement of $61.7 million in aggregate

PDL BioPharma to Present at 2010 Global Hunter Securities Healthcare Conference INCLINE VILLAGE, Nev., Aug 11, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that Christine Larson, the company's vice president and chief financial officer, will present at

PDL BioPharma Announces Retirement of $61.6 Million of 2.75% Convertible Notes due August 2023 for Common Stock INCLINE VILLAGE, Nev., Aug 05, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) announced today that it has entered into separate privately negotiated agreements

PDL BioPharma to Present at BMO Capital Markets' 10th Annual Focus on Healthcare Conference INCLINE VILLAGE, Nev., July 29, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will

PDL BioPharma Announces Second Quarter 2010 Financial Results INCLINE VILLAGE, Nev., July 28, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today reported financial results for the second quarter ended June 30, 2010. "Our licensed products continue to generate substantial

Print PageEmail PageRSS FeedsEmail AlertsFinancial Tear Sheet News Release Print PageEmail PageRSS FeedsEmail AlertsFinancial Tear Sheet News Release INCLINE VILLAGE, Nev., July 20, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that the Company will

PDL BioPharma Provides Second Quarter 2010 Revenue Guidance of Approximately $120 Million INCLINE VILLAGE, Nev., June 15, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue guidance for the second quarter ended June 30, 2010 of approximately $120

PDL BioPharma to Present at Ninth Annual JMP Securities Research Conference on May 12, 2010 INCLINE VILLAGE, Nev., May 4, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will

Conference Call Today at 4:30 p.m. Eastern Time -

PDL BioPharma to Announce First Quarter 2010 Financial Results and Hold Conference Call on April 29, 2010 INCLINE VILLAGE, Nev., April 22, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that the Company will hold a conference call and webcast on Thursday,

PDL BioPharma Completes April 1 Special Dividend Payment INCLINE VILLAGE, Nev., April 5, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it has paid the April 1, 2010 special dividend payment of $0.50 per share to all stockholders owning shares of PDL as

PDL BioPharma Clarifies $13.00 Cost Basis in Facet Biotech Corporation INCLINE VILLAGE, Nev., March 24, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that the cost basis for shares of Facet Biotech Corporation (Facet) (Nasdaq: FACT) distributed to PDL

PDL BioPharma To Hold Annual Meeting of Stockholders on June 9, 2010 INCLINE VILLAGE, Nev., March 16, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that the company will hold its annual meeting of stockholders on Wednesday, June 9, 2010 at 9:00a.m.

Company Clarifies Facet Stock Distribution Value -

PDL BioPharma to Present at the Cowen and Company 30th Annual Health Care Conference on March 9, 2010 INCLINE VILLAGE, Nev., March 3, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive